Delving into the Latest Updates on Packaging Coordinators Holdings LLC with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Otorhinolaryngologic Diseases

Nervous System Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Chemical drugs	1

Top 5 Target	Count

30S subunit(30S ribosomal subunit)	1
CGRP receptor(Calcitonin gene-related peptide type 1 receptor)	1

The antibacterial activity of Sarecycline against clinical strains of the main acne-related pathogens (Propionibacterium acnes, Staphylococcus epidermidis, and Staphylococcus aureus) was studied by culturing, isolating, and identifying the main acne-related pathogens (Propionibacterium acnes, Staphylococcus epidermidis, and Staphylococcus aureus) from the lesions of patients with acne vulgaris

Start Date12 Oct 2022

Sponsor / Collaborator

Almirall LLC

[+3]

CTR20220692 / CompletedPhase 3

一项旨在研究RIMEGEPANT 口腔崩解片在中国受试者中治疗急性偏头痛的长期安全性干预性、III 期、单组、开放性研究

[Translation] An interventional, phase III, single-arm, open-label study to investigate the long-term safety of RIMEGEPANT orally disintegrating tablets for the treatment of acute migraine in Chinese subjects

主要目的：评估75 mg Rimegepant ODT【按需服用（PRN）】的长期安全性和耐受性。次要目的：相对于观察期，评估受试者接受75 mg Rimegepant ODT（PRN）长期治疗期间的偏头痛发作的头痛天数和严重程度。

[Translation]

Primary Objective: To evaluate the long-term safety and tolerability of rimegepant ODT 75 mg taken as needed (PRN). Secondary Objective: To evaluate the number of headache days and severity of migraine attacks during long-term treatment with rimegepant ODT 75 mg (PRN) compared to the observation period.

Start Date19 May 2022

Sponsor / Collaborator

Biohaven Pharmaceutical Ireland DAC

[+3]

CTR20211314 / CompletedPhase 3

一项旨在评估中、重度寻常性痤疮患者接受约1.5 mg/kg/天口服Sarecycline 治疗12 周后疗效和安全性的随机、多中心、双盲、安慰剂对照的临床试验

[Translation] A randomized, multicenter, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of 1.5 mg/kg/day oral sarecycline in patients with moderate to severe acne vulgaris after 12 weeks of treatment

主要目的：本试验的主要目的是根据炎性病灶计数，评价口服Sarecycline 与安慰剂相比治疗中重度寻常性痤疮患者的疗效。次要目的：是根据不良事件、生命体征、体格检查和临床实验室检查来评价口服Sarecycline的安全性。

[Translation]

Primary objective: The primary objective of this trial is to evaluate the efficacy of oral Sarecycline compared with placebo in the treatment of moderate to severe acne vulgaris patients based on inflammatory lesion counts. Secondary objective: To evaluate the safety of oral Sarecycline based on adverse events, vital signs, physical examinations, and clinical laboratory tests.

Start Date16 Nov 2021

Sponsor / Collaborator

Almirall LLC

[+3]

100 Clinical Results associated with Packaging Coordinators Holdings LLC

Login to view more data

0 Patents (Medical) associated with Packaging Coordinators Holdings LLC

Login to view more data

100 Deals associated with Packaging Coordinators Holdings LLC

Login to view more data

100 Translational Medicine associated with Packaging Coordinators Holdings LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Sarecycline Hydrochloride ( 30S subunit )	Acne Vulgaris More	Phase 3
Rimegepant Sulfate ( CGRP receptor )	Acute migraine More	Phase 3
Dexlansoprazole ( Proton pump )	Erosive esophagitis More	Suspended